Artikel ; Online: Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials.
2023 Band 77, Seite(n) 154344
Abstract: Purpose: The optimal amount of anticoagulation for critically ill COVID-19 patients is controversial. Therefore, we aimed to evaluate the efficacy and safety of escalated doses of anticoagulation in critically ill patients with severe COVID-19.: ... ...
Abstract | Purpose: The optimal amount of anticoagulation for critically ill COVID-19 patients is controversial. Therefore, we aimed to evaluate the efficacy and safety of escalated doses of anticoagulation in critically ill patients with severe COVID-19. Materials and methods: We conducted a systematic search of three major databases, including PubMed, Cochrane Library, and Embase, from inception to May 2022. Randomized controlled trials (RCTs) were included comparing therapeutic or intermediate doses to standard prophylactic doses of anticoagulants in critically ill COVID-19 patients, with heparins as the only anticoagulation therapy considered. Results: Out of the six RCTs, 2130 patients were administered escalated dose anticoagulation (50.2%) and standard thromboprophylaxis therapy (49.8%). The escalated dose showed no significant impact on mortality (RR, 1.01; 95% CI, 0.90-1.13). Although there was no significant difference in DVT (RR, 0.81; 95% CI, 0.61-1.08), the risk of PE was significantly reduced in patients receiving escalated dose anticoagulation (RR, 0.35; 95% CI, 0.21-0.60), with an increased risk of bleeding events (RR, 1.65; 95% CI, 1.08-2.53). Conclusion: This systematic review and meta-analysis fail to support escalated anticoagulation doses to reduce mortality in critically ill COVID-19 patients. However, higher doses of anticoagulants appear to reduce thrombotic events while increasing the risk of bleeding effectively. |
|||||
---|---|---|---|---|---|---|
Mesh-Begriff(e) | Humans ; Heparin/adverse effects ; Heparin, Low-Molecular-Weight/therapeutic use ; Critical Illness ; COVID-19 ; Neoplasms ; Randomized Controlled Trials as Topic ; Anticoagulants/adverse effects ; Hemorrhage/chemically induced ; Venous Thromboembolism/drug therapy | |||||
Chemische Substanzen | Heparin (9005-49-6) ; Heparin, Low-Molecular-Weight ; Anticoagulants | |||||
Sprache | Englisch | |||||
Erscheinungsdatum | 2023-05-25 | |||||
Erscheinungsland | United States | |||||
Dokumenttyp | Meta-Analysis ; Systematic Review ; Journal Article ; Review | |||||
ZDB-ID | 632818-0 | |||||
ISSN | 1557-8615 ; 0883-9441 | |||||
ISSN (online) | 1557-8615 | |||||
ISSN | 0883-9441 | |||||
DOI | 10.1016/j.jcrc.2023.154344 | |||||
Signatur |
|
|||||
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 2152: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.